New insights into the pathophysiology of ITP, driven by research on immune dysregulation and genetic predispositions, have led to the introduction of targeted therapies, such as thrombopoietin receptor agonists and novel immunomodulatory agents, which offer more effective and personalized treatment options. This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.